BioSpace News Archive

Oculogica, a leader in concussion diagnostics, today announced launch of the new EyeBOX device following FDA clearance earlier this year.

Molecular Templates, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bodies, which are differentiated, targeted, biologic therapeutics for cancer and other serious diseases, will participate in several upcoming investor conferences.

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), today announced that its wholly-owned subsidiary, Quoin Pharmaceuticals, Inc., has extended its exclusive Distribution Agreement with ER-Kim, a partner for biotech companies in Central and Eastern Europe (“CCE”), for QRX003, the Company’s investigational treatment for Netherton Syndrome.

Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, today announced that it has received $2.3 million in non-dilutive funding as an approved participant of the Technology Business Tax Certificate Transfer Program (the “Program”) sponsored by the New Jersey Economic Development Authority (“NJEDA”).

SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that it will report financial results for the fourth quarter and full year 2021 after market close on Tuesday, March 29, 2022.

Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced plans to present virtually at the 42nd Annual Cowen Health Care Conference.

Bringing together world-class experts in biophysics, pluripotent stem cell biology and gene editing, the newly created SAB will guide the development of proprietary C-StemTM technology platform and in-house cell therapy programs.

The Offering consisted of the issuance of an aggregate of 8,606,071 Units at a price of $0.14 per Unit.

The Compensation Committee and Board of Directors of the Company have approved the Options grant and no materially contrary view or ‎abstention ‎was expressed or made by any director in relation to the Options grant

Amrita University has developed a device for home-monitoring of glucose and blood pressure.